JANX · CIK 0001817713
What Janux Therapeutics, Inc. told the SEC could break it.
Janux's disclosures are those of a pre-commercial biotech dependent on a thin web of single relationships. It has limited manufacturing arrangements and expects the bulk drug substance for each of its candidates to come from single-source suppliers for the foreseeable future — and its principal supplier of critical biological materials, WuXi Biologics, is in China, so proposed U.S. legislation, executive action or sanctions could disrupt that supply. All of its revenue across 2023-2025 came from a single collaboration partner, and as a company not expecting product sales for years, it ran a $113.6 million net loss in 2025 and will need substantial additional funding, exposing it to dilution and financing-market risk.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- Bulk Drug Substance for each product candidate from single-source suppliershigh
Janux has limited manufacturing arrangements and expects the Bulk Drug Substance (BDS) for each of its product candidates to be covered only by single-source suppliers for the foreseeable future, risking insufficient quantity, acceptable cost or quality and delaying development.
“We currently have limited manufacturing arrangements and expect that the Bulk Drug Substance (BDS) for each of our product candidates will only be covered by single source suppliers for the foreseeable future.”
SEC filing →As of 2026
Customer concentration
- all revenue from a single collaboration customermedium
All of Janux's revenue in 2025, 2024 and 2023 came from a single customer (its collaboration partner); as a pre-commercial biotech, its near-term revenue depends entirely on that one collaboration relationship.
“For the years ended December 31, 2025, 2024 and 2023 , all of the Company's revenue related to a single customer.”
SEC filing →As of 2026
Liquidity & debt
- recurring net losses; need for substantial additional funding (no product revenue for years)medium
Janux incurred a $113.6M net loss in 2025 (vs. $69.0M in 2024) and does not expect product-sales revenue for many years, so it will need substantial additional funding to continue operations — exposing it to dilution and financing-market risk.
“Because we do not expect to generate revenue from product sales for many years, if at all, we will need to obtain substantial additional funding in connection with our continuing operations and expected increases in expenses.”
SEC filing →As of 2026
Regulatory & policy
- U.S.-China legislation/sanctions threatening reliance on WuXi Biologicsmedium
Janux's principal supplier of critical biological materials, WuXi Biologics, is in China; proposed U.S. legislation (e.g., BIOSECURE-type restrictions), executive action or sanctions could restrict or prohibit working with WuXi, disrupting the supply of materials and tariffs raise R&D costs.
“Any U.S. executive action, legislative action, or potential sanctions with China could materially impact our work with WuXi Biologics.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“we will manufacture and supply Licensed Products to BMS for early clinical development for a limited time period. BMS is obligated to use commercially reasonable efforts to develop and seek regulatory approval of and commercialize at least one Licensed Product in the U.S.”
Cited →“On December 15, 2020, we and Merck Sharp & Dohme Corp. (Merck), entered into a research”
Cited →
Its suppliers
WuXi Biologics (Cayman) Inc.
“Currently, several of our suppliers are located outside of the United States, and our principal supplier of critical biological materials, WuXi Biologics, is located in China.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch